Eagle Asset Management Inc. Raises Stock Holdings in Novo Nordisk A/S (NYSE:NVO)

Eagle Asset Management Inc. lifted its holdings in Novo Nordisk A/S (NYSE:NVO) by 10.4% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 17,893 shares of the company’s stock after purchasing an additional 1,680 shares during the quarter. Eagle Asset Management Inc.’s holdings in Novo Nordisk A/S were worth $2,131,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of the business. 1620 Investment Advisors Inc. bought a new stake in shares of Novo Nordisk A/S in the 2nd quarter worth about $25,000. Strategic Investment Solutions Inc. IL bought a new stake in Novo Nordisk A/S during the second quarter worth approximately $25,000. Gilliland Jeter Wealth Management LLC raised its position in Novo Nordisk A/S by 200.0% during the second quarter. Gilliland Jeter Wealth Management LLC now owns 180 shares of the company’s stock valued at $26,000 after purchasing an additional 120 shares during the period. Halpern Financial Inc. lifted its stake in shares of Novo Nordisk A/S by 113.0% in the 2nd quarter. Halpern Financial Inc. now owns 213 shares of the company’s stock valued at $30,000 after purchasing an additional 113 shares during the last quarter. Finally, Abound Wealth Management boosted its holdings in shares of Novo Nordisk A/S by 257.4% in the 2nd quarter. Abound Wealth Management now owns 218 shares of the company’s stock worth $31,000 after purchasing an additional 157 shares during the period. Institutional investors own 11.54% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently weighed in on NVO shares. BMO Capital Markets decreased their price target on Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating on the stock in a report on Thursday, October 17th. Cantor Fitzgerald restated an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. Finally, StockNews.com upgraded shares of Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a report on Friday, November 1st. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Novo Nordisk A/S has an average rating of “Buy” and a consensus target price of $144.50.

Novo Nordisk A/S Stock Down 0.5 %

Shares of NVO opened at $104.56 on Tuesday. The firm has a market capitalization of $469.22 billion, a P/E ratio of 33.84, a P/E/G ratio of 1.35 and a beta of 0.42. Novo Nordisk A/S has a 12-month low of $94.73 and a 12-month high of $148.15. The firm has a fifty day moving average price of $114.83 and a 200-day moving average price of $128.64. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.